XPHOZAH: Established safety and tolerability profile across three phase 3 clinical trials in 754 XPHOZAH-treated patients with hyperphosphatemia1
Most common adverse reactions1
- 43-53% incidence of diarrhea: the only adverse reaction reported in ≥5% of patients treated with XPHOZAH in the phase 3 clinical trials1
- Majority mild-to-moderate
- 5% of patients experienced severe diarrhea1
- If diarrhea occurred, it was typically reported soon after initiation and resolved over time or with dose reduction
- Similar rate of SAEs among XPHOZAH and sevelamer-treated patients in PHREEDOM2
SAE = serious adverse event.